SCHEDULE 13D/A: Major Shareholder Ezbon International Sells 3 Million Shares of Stoke Therapeutics
Beneficial Ownership Update
Ezbon International Ltd., a reporting person, has significantly reduced its stake in Stoke Therapeutics, Inc. by selling 3 million shares in an open market transaction.
Summary
- Ezbon International Ltd. sold 3,000,000 shares of Stoke Therapeutics, Inc. common stock on June 4, 2025.
- The shares were sold in an open market transaction at a price of $10.20 per share, totaling $30,600,000.
- Following the sale, the beneficial ownership percentages for the reporting persons are: Blue Horizon Enterprise Ltd. holds 5.4% (2,967,621 shares), Ezbon International Ltd. holds 1.7% (938,560 shares), Montrago Trustees Ltd. holds 7.2% (3,906,181 shares), and Skorpios Trust holds 7.2% (3,906,181 shares).
- The percentages are calculated based on 54,596,924 shares of Stoke Therapeutics' common stock outstanding as of April 30, 2025, as reported in the company's Form 10-Q filed on May 13, 2025.
- This filing is Amendment No. 4 to the original Schedule 13D filed on June 30, 2021, updating previous amendments.
Sentiment
Score: 3
Explanation: The significant reduction in stake by a major beneficial owner is typically viewed negatively by the market, suggesting a potential lack of confidence or a strategic exit.
Positives
- NA
Negatives
- Ezbon International Ltd., a significant beneficial owner, sold 3,000,000 shares, representing a substantial reduction in its stake.
- The sale of a large block of shares by a major investor can be perceived as a lack of confidence in the company's future prospects or a strategic divestment.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing details a change in beneficial ownership for a specific company and does not provide broader industry context or trends.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders may react negatively to the news of a major investor reducing its stake, potentially leading to downward pressure on the stock price.
- The transaction could raise questions among investors regarding the long-term outlook of Stoke Therapeutics, Inc.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2021-06-30 | Original Schedule 13D filed by the Reporting Persons. |
| 2024-04-18 | Amendment No. 1 to Schedule 13D filed. |
| 2024-09-23 | Amendment No. 2 to Schedule 13D filed. |
| 2024-12-27 | Amendment No. 3 to Schedule 13D filed. |
| 2025-04-30 | Date as of which 54,596,924 shares of the Issuer's common stock were outstanding, used for percentage calculation. |
| 2025-05-13 | Date of the Company's Quarterly Report on Form 10-Q filing, reporting shares outstanding. |
| 2025-06-04 | Date of event requiring filing of this statement; Ezbon International Ltd. sold 3,000,000 shares. |
| 2025-06-06 | Date of signing of this Amendment No. 4 and the Joint Filing Agreement. |
Recommendation
sellKeywords
Stoke Therapeutics, STOK, Schedule 13D, beneficial ownership, share sale, institutional investor, SEC filing, equity divestment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.